Ziihera
Ziihera ingredients
| Active ingredient | Strength |
|---|---|
| Zanidatamab | 50 mg/mL |
What Ziihera is used for
The FDA lists the approved uses on the official label (below). In the EU, zanidatamab is approved as Ziihera for:
Ziihera as monotherapy is indicated for the treatment of adults with unresectable locally advanced or metastatic HER2-positive (IHC3+) biliary tract cancer (BTC) previously treated with at least one prior line of systemic therapy (for biomarker-based patient selection, see section 4.2).
EU wording from the European Medicines Agency; US approved uses can differ.
Key facts
- Brand
- Ziihera
- Generic name
- Zanidatamab-hrii
- Made by
- Jazz Pharmaceuticals, Inc.
- Forms
- Injection, Powder, Lyophilized, For Solution
- Given
- Intravenous
- Drug class
- Bispecific HER2-directed Antibody
- FDA approval
- Biologic licence (BLA) BLA761416
- On the US market since
- 2024
Official information
- Ziihera prescribing information (FDA label) on DailyMed
- MedlinePlus drug information (search for Zanidatamab-hrii)
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Ziihera?
Ziihera (Zanidatamab-hrii) is a cancer medicine made by Jazz Pharmaceuticals, Inc., approved by the US FDA.
What are the ingredients of Ziihera?
Ziihera contains Zanidatamab (50 mg/mL).
Is Ziihera approved in Europe?
The same active substance is approved in the EU as Ziihera.
From the FDA National Drug Code directory (open.fda.gov, public domain) and the European Medicines Agency medicines list. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, USA